NEWS

News Articles

GeoVax Receives Notice of Allowance for Ebola Vaccine Patent

October 14, 2021

Single-dose of GEO-EM01 Provided 100% Protection in Lethal Challenge Evaluation ATLANTA, GA, October 14, 2021 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for Patent Application No. 15/543,139 entitled “Replication-Deficient…

Read More

Francis Collins to step down as director of the National Institutes of Health

October 8, 2021

Francis S. Collins, M.D., Ph.D., today announced his decision to end his tenure as the director of the National Institutes of Health by the end of the year. Dr. Collins is the longest serving presidentially appointed NIH director, having served three U.S. presidents over more than 12 years. “It has been an incredible privilege to…

Read More

Emory University research helps develop potential COVID-19 treatment drug

October 8, 2021

Emory University researchers have helped develop an oral antiviral drug that could treat COVID-19, a potential breakthrough in the ongoing pandemic. Merck and Ridgeback Biotherapeutics announced Friday they plan to seek emergency use authorization from federal health officials for the drug, molnupiravir, after research showed “compelling” results in clinical trials. If approved, it would be…

Read More

Pfizer and Voyager Launch $630 Million Gene Therapy Technology Pact

October 8, 2021

Cambridge, Mass.-based Voyager Therapeutics entered a deal with Pfizer, allowing the latter to exercise options to license novel capsids for gene therapies. Specifically, the deal enables Pfizer to license novel capsids created by Voyager’s RNA-driven TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) screening technology. Pfizer will pay $30 million upfront and $20 million in exercise fees for a pair…

Read More

Meet Neumora, Arch’s $500M, Amgen-partnered play for the targeted future of neuroscience R&D

October 8, 2021

Arch Venture Partners has taken the lid off its big bet on neuroscience. Having quietly put the startup together over the past 18 months, Thursday Arch unveiled Neumora Therapeutics—a biotech that starts life with $500 million, a collaboration with Amgen and a pipeline of eight prospects.   Neumora represents a test of the idea that neuroscience is…

Read More

The Nobel Prize in Chemistry 2021 was awarded jointly to Benjamin List and David W.C. MacMillan “for the development of asymmetric organocatalysis.”

October 8, 2021

Building molecules is a difficult art. Benjamin List and David MacMillan are awarded the Nobel Prize in Chemistry 2021 for their development of a precise new tool for molecular construction: organocatalysis. This has had a great impact on pharmaceutical research, and has made chemistry greener. Many research areas and industries are dependent on chemists’ ability…

Read More